Initiation of buprenorphine during incarceration and retention in treatment upon release.
Document Type
Article, Non peer-reviewed
Publication Date
6-21-2013
Abstract
We report here on a feasibility study of initiating buprenorphine/naloxone prior to release from incarceration and linking participants to community treatment providers upon release. The study consisted of a small number of Rhode Island (RI) prisoners (N = 44) diagnosed with opioid dependence. The study design is a single arm, open-label pilot study with a 6-month follow up interview conducted in the community. However, a natural experiment arose during the study comparing pre-release initiation of buprenorphone/naloxone to initiation post-release. Time to post-release prescriber appointment (mean days) for initiation of treatment outside Rhode Island Department of Corrections (RIDOC) versus inside RIDOC was 8.8 and 3.9, respectively (p = .1). Median post release treatment duration (weeks) for outside RIDOC versus inside RIDOC was 9 and 24, respectively (p = .007). We conclude that initiating buprenorphine/naloxone prior to release from incarceration may increase engagement and retention in community-based treatment.
Recommended Citation
Zaller, Nickolas; McKenzie, Michelle; Friedmann, Peter D.; Green, Traci C.; McGowan, Samuel; and Rich, Josiah D., "Initiation of buprenorphine during incarceration and retention in treatment upon release." (2013). All Scholarly Works. 8360.
https://scholarlycommons.libraryinfo.bhs.org/all_works/8360
PMID
23541303
